1 July 2015 in Journal of Bone and Joint Surgery
Tumor-induced osteomalacia is a rare and fascinating paraneoplastic syndrome usually caused by a small, benign phosphaturic mesenchymal tumor. Most tumors are treated surgically, but we are unaware of any reports that compare the results of curettage and segmental resection for lesions in long bones. Seventeen patients (ten male and seven female) with tumor-induced osteomalacia lesions in long bones, who underwent surgical treatment from December 2004 to August 2013 in our hospital, were included in this retrospective study. The mean follow-up (and standard deviation) was 35 ± 27 months (range, twelve to 116 months). The characteristics of the tumor and the effects of different surgical treatments (curettage compared with segmental resection) were evaluated. All patients showed typical clinical characteristics of tumor-induced osteomalacia, including elevated serum fibroblast growth factor-23 (FGF-23); 82% of tumors were in the epiphysis, and 82% grew eccentrically. The mean maximum diameter of the tumors was 2.4 ± 2.0 cm. The complete resection rates were similar for curettage (67%) and segmental resection (80%). However, the recurrence rate after curettage (50%) was higher than that after segmental resection (0%). The complete resection rate for secondary segmental resection (75%) was not different from that for primary segmental resection (83%). All of our cases of tumor-induced osteomalacia were caused by phosphaturic mesenchymal tumors. After successful removal of tumors, serum FGF-23 returned to normal within twenty-four hours and serum phosphorus levels returned to normal at a mean of 6.5 ± 3.5 days. Most lesions in long bones are located in the epiphysis, so curettage is first suggested to maintain joint function. If curettage is incomplete or there is a recurrence, secondary segmental resection should be considered curative. Changes of serum FGF-23 and phosphorus levels before and after the operation may be of prognostic help. Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
2 August 2019 in Aging Clinical and Experimental Research
Healthy aging is defined as the process of developing and maintaining the functional ability that enables wellbeing in older age. Healthy aging is dependent upon intrinsic capacity, a composite of physical and mental capacities, and the environment an individual inhabits and their interactions with it. Maintenance of musculoskeletal health during aging is a key determinant of functional ability. Sarcopenia, osteoporosis and osteoarthritis, are a triad of musculoskeletal diseases of aging that are major contributors to the global burden of disease and disability worldwide. The prevention and management of these disorders is of increasing importance with pressure mounting from the aging population. In a new initiative, the Chinese Medical Association, Chinese Society of Osteoporosis and Bone Mineral Research, and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases jointly organized a symposium to discuss current practices and policies in the management of musculoskeletal aging. The meeting allowed experts from Europe and China to share their experience and recommendations for the management of these three major diseases. Discussing and analyzing similarities and differences in their practice should lead, through a mutual enrichment of knowledge, to better management of these diseases, in order to preserve intrinsic capacity and retard the age-related degradation of physical ability. In future, it is hoped that sharing of knowledge and best practice will advance global strategies to reduce the burden of musculoskeletal disease and promote healthy aging tailored to meet the individual patient’s needs.
21 May 2010 in Osteoporosis International
14 July 2009 in Osteoporosis International
9 May 2025 in eClinicalMedicine
This study aims to evaluate the difference between dual-energy X-ray absorptiometry (DXA) vs. quantitative computed tomography (QCT) in the diagnosis of osteoporosis (OP), and to discuss the impact of this difference on OP clinical practice, as well as the potential reasons for the disparities. In this systematic review and meta-analysis (PROSPERO ID: CRD42024599632), we searched Medline, Embase, Scopus, Web of Science, and Cochrane Library databases for studies published from the inception to September 14, 2024. Studies using both QCT and DXA to diagnose OP in the same population were included, and 2 independent reviewers extracted the data by following the PRISMA statement. Pooled odds ratios (ORs) with 95% confidence interval (CI) were estimated using random effects model under heterogeneity. A total of 19 studies with 3939 cases were included. The meta-analysis results indicated that QCT identified significantly more OP patients than DXA in the same population (OR: 4.91, 95% CI: 3.19–7.54; p < 0.0001). Subgroup analysis revealed that the higher diagnostic rate of QCT over DXA in diagnosing OP is significantly stronger in males (OR: 8.45, 95% CI: 3.80–18.77; p < 0.0001) than in females (OR: 2.11, 95% CI: 1.53–2.90; p < 0.0001). Furthermore, among the population aged ≥65 years (OR: 6.01, 95% CI: 3.45–10.47; p < 0.0001), the differences between QCT and DXA in diagnosing OP were significantly greater than those in the population aged <65 years (OR: 2.27, 95% CI: 1.55–3.33; p < 0.0001). The incidence of OP examined by QCT is significantly higher than that of DXA. The different prevalence rates obtained from the two diagnostic techniques will inevitably complicate the prevention and treatment of OP, as well as the selection of cases in drug clinical trials. This study highlighted this confusion and aims to motivate relevant organizations or institutions to address this challenge. There was no funding for this study.
26 August 2009 in Haemophilia